Oncimmune Share Discussion Threads

[brummy_git] 05/3/2024 14:10

In this conversation, CEO Martin Gouldstone of Oncimmune - a leading life sciences firm offering autoantibody profiling that is used to enable precision medicine within the Biopharma industry – takes me through:

00:00 What the company does and the current demand picture across the sector.

09:15 recent contract wins and update on #ONC's commercialisation strategy.

[brummy_git] 24/11/2023 14:09

In this fascinating interview, CEO Martin Gouldstone of Oncimmune - a global leader in immune biomarkers and immunodiagnostics – takes me through the business' new strategy & considerable market opportunity.

[brummy_git] 12/10/2023 08:19

Encouraging new developments from IPR rich life science firm Oncimmune.

All the details here.

[pugugly] 01/8/2023 15:05

Some investors seem unhappy about management changes and dumping - Thoughts?

[w t tutte] 26/6/2023 10:09

Looks to me that the CEO might have been pushed rather than jumped. It feels like someone took a hard headed look and said we can we save @650k per year with minimal operational impact.

I have sympathy for the CEO but this is a needed and refreshing approach.

[kt_aim] 04/6/2023 17:31

brummy_git

Positive news?

You must definitely be on the payroll

The news is horrific …

[40 fathoms] 04/6/2023 07:04

Once again they have done a terrible job with the communication to market.

Here are the key points of interest to me and that I was able to extract.

-With closure of the Freenome deal they will be in a net cash position.
-Contracted Order Book at 1st March = Euro 3.5 million
-Post 1st March Known Contracts (Freenome) = Euro 2.3 million (minimum)
-Additional Contracts expected to be signed
-Roche Collaborations moving in a promising direction
-The difference between the Current Order book, given in the Chairmans statement and the 1st March Order book suggests that Euro 2.2 million of revenue has already been booked in the second half.
- significant costs will be removed with sale of CDT Lung, related administration and research & development costs, were £1.23M in the first half.
- Once we get clean accounts, cashflow breakeven for the business would appear to be at about a revenue of £4.00M to £4.25M.

[z1co] 01/6/2023 10:11

JakAss try living in the real world you muppet.

The question was why do you delete your old posts?.

[z1co] 31/5/2023 23:57

JakAss,you complete plonker for reference this post stays:

=========================================================================
JakNife 31 May '23 - 22:48 - 271 of 272
0 0 2
What a pile of poo this is

* negligible revenue
* revenue down (not a growth company)
* material P&L losses £4,110 loss cf proforma cash
* negative tangible net assets of £9.7m
* a fat cat CEO that's paying himself an exorbitant amount

By the time that the finals are published cash will be running low again and they'll need to raise funds.

JakNife

[z1co] 31/5/2023 23:52

Hey JakAss

Never mind about this company why do you delete your old posts you pile of poo ???

[eva_1989] 31/5/2023 11:15

I dont know what Trek from LSE smoking but i badly need same ;)


He thought to pump before open so that he can sell to others...




Hi R00st3R,

I think todays interims answer your questions. All good at ONC. Well actually very good!

Should be a cracking day today!

Pity some of the revs got delayed but there is a line of sight and perhaps most importantly a change in sentiment.

Wish I could buy more at this price!

Usual caveats

Trek

[brummy_git] 31/5/2023 09:33

H1'23 results out today from Oncimmune. All the details here.

[brummy_git] 22/5/2023 09:26

Very positive M&A and contract news from global immunodiagnostics group Oncimmune today.

All the details here.

[w t tutte] 28/2/2023 08:13

Agreed, many a slip between the cup and the lip, but an easy buy if they are able to deal with the refinancing.

[40 fathoms] 28/2/2023 01:17

Link to post results interview

[40 fathoms] 27/2/2023 21:16

These numbers are for the 15 months (changed accounting period) to August last year.

Quite a bit has happened since then, not least of which is a big increase in the revenue at immunoinsights business and a smallish CR. As they said in the release today, their income in the 6 months since Aug 22 is higher than for the 15 months reported. They also say they will be operationally cash profitable for the FY ending Aug 23.

[40 fathoms] 27/2/2023 08:07

There is no way IPL will pull the plug on a business that is clearly able to repay them, they will ask for a pound of flesh but not pull the plug, after all lending to healthcare startup is their business.

[40 fathoms] 27/2/2023 07:38

"Business continues to perform in line with previously reported expectations, and the Group is now expecting to be operating cashflow positive in FY2023."